Edition:
United States

Gilead Sciences Inc (GILD.OQ)

GILD.OQ on NASDAQ Stock Exchange Global Select Market

64.29USD
1:59pm EDT
Change (% chg)

$-0.40 (-0.62%)
Prev Close
$64.69
Open
$64.73
Day's High
$64.78
Day's Low
$64.23
Volume
763,776
Avg. Vol
2,697,508
52-wk High
$88.84
52-wk Low
$63.89

Latest Key Developments (Source: Significant Developments)

Gilead Sciences says Genvoya tablets, for HIV-1 treatment, is now listed in multiple provinces in Canada
Thursday, 4 May 2017 09:44am EDT 

May 4 (Reuters) - Gilead Sciences Inc : :Genvoya tablets, for treatment of HIV-1 infection is now listed in multiple provinces in Canada as well as in NIHB drug plan for First Nations, Inuit.  Full Article

Gilead Sciences says Nova Scotia lists Epclusa on public drug plan to treat all six genotypes of Chronic Hepatitis C infection
Monday, 1 May 2017 07:00am EDT 

May 1 (Reuters) - Gilead Sciences Inc :Gilead sciences inc - nova scotia lists epclusa on public drug plan to treat all six genotypes of chronic hepatitis c infection.Effective immediately, nova scotia will provide public access to epclusa (sofosbuvir/velpatasvir) tablets.  Full Article

Gilead announces results from 2 Phase 2 studies evaluating Harvoni tablets in chronic hepatitis C infected patient populations
Friday, 21 Apr 2017 12:00pm EDT 

April 21 (Reuters) - Gilead Sciences Inc ::Results from 2 Phase 2 studies evaluating Harvoni tablets in chronic hepatitis C infected patient populations.Studies demonstrated HCV cure rates of 99 percent in children aged 6 to 11 years, and 100 percent in adult patients co-infected with HCV and HBV.In Karen Murray led study, 1 treatment-naïve genotype 1 patient relapsed; other patients achieved SVR12, primary efficacy endpoint .In Chun-Jen Liu led study, 3 patients had serious adverse events that were not considered to be drug-related .Most common adverse events reported from Chun-Jen Liu led study were headache, upper respiratory infection, fatigue .  Full Article

FDA approves two of Gilead's hepatitis C drugs for pediatric patients
Friday, 7 Apr 2017 10:11am EDT 

Gilead Sciences Inc : U.S. FDA approves new indications for Harvoni and Sovaldi in pediatric patients 12 years and older with chronic hepatitis C infection . Harvoni, Sovaldi each have boxed warning in their respective product labels .Boxed warning for the two drugs relate to risk of hepatitis B virus reactivation in HCV/HBV co-infected patients.  Full Article

Gilead Sciences CEO John Milligan's 2016 total compensation was $13.9 mln- SEC Filing
Monday, 27 Mar 2017 05:36pm EDT 

Gilead Sciences Inc : Gilead Sciences Inc- CEO John F. Milligan's 2016 total compensation was $13.9 million- SEC Filing . Executive chairman John Martin's FY 2016 total compensation was $10.4 million . CFO Robin Washington's FY 2016 total compensation was $5.1 million versus $5.6 million in FY 2015 .Chief Scientific Officer Norbert Bischofberger's FY 2016 total compensation was $6.2 million versus $6.95 million in FY 2015.  Full Article

Gilead Sciences lists EPCLUSA on public drug plan to treat chronic hepatitis C infection
Tuesday, 21 Mar 2017 04:00pm EDT 

Gilead Sciences Inc - :British Columbia lists EPCLUSA on public drug plan to treat all six genotypes of chronic hepatitis C infection.  Full Article

Gilead Sciences says EPCLUSA added to Liste des médicaments de la RAMQ
Monday, 20 Mar 2017 12:25pm EDT 

Gilead Sciences Inc :EPCLUSA, to treat all six genotypes of chronic Hepatitis C infection, added to Liste des médicaments de la RAMQ.  Full Article

Galapagos announces two Phase 2 studies with filgotinib in small bowel and fistulizing Crohn's disease
Friday, 10 Mar 2017 01:30am EST 

Galapagos Nv : announces two new phase 2 studies investigating filgotinib in small bowel Crohn's disease as well as in fistulizing Crohn's disease .studies are being led by filgotinib collaboration partner Gilead Sciences.  Full Article

Gilead Sciences Canada says Ontario to list Epclusa on public drug plan to treat all six genotypes of chronic Hepatitis C infection
Wednesday, 22 Feb 2017 11:36am EST 

Gilead Sciences Canada :Gilead Sciences Canada- effective feb 28, ontario to list epclusa on public drug plan to treat all six genotypes of chronic hepatitis c infection.  Full Article

Gilead receives approval in Canada for Odefsey for treatment of HIV-1 infection
Thursday, 16 Feb 2017 11:30am EST 

Gilead Sciences Inc :Gilead receives approval in Canada for Odefsey for the treatment of HIV-1 infection.  Full Article

More From Around the Web

BRIEF-Gilead says stockholders did not approve proposal requesting board take steps to adopt policy that chairman of board be independent director

* Gilead-Stockholders did not approve proposal requesting board take steps to adopt policy that chairman of board be independent director-sec filing Source text (http://bit.ly/2r9rtBo) Further company coverage: